Stay updated with breaking news from Palisade Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) was the target of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 35,200 shares, a decrease of 80.3% from the April 30th total of 178,500 shares. Currently, 3.8% of the shares of the company are […]
Maxim Group reissued their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a report released on Wednesday, Benzinga reports. Maxim Group currently has a $22.50 price objective on the stock. Palisade Bio Price Performance NASDAQ:PALI opened at $7.08 on Wednesday. The company’s 50 day moving average is $5.70 and its 200-day […]
Shares of Palisade Bio, Inc. (PALI) surged over 37% on Tuesday morning after the company announced a strategic collaboration with Strand Life Sciences to advance the precision medicine approach.
Palisade Bio entered into a collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative colitis (UC) therapy and provides the company access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.
Maxim Group restated their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $22.50 price target on the stock. Palisade Bio Price Performance Shares of Palisade Bio stock opened at $4.71 on Tuesday. Palisade Bio has a 1 […]